Itabashi CampusA research group led by Professor Suzuki of the Faculty of Pharma-Science has developed a new polymer-bound anticancer drug.

On Monday, April 8, 2024, Ryo Suzuki, Teikyo University Faculty of Pharmaceutical Sciences Drug Delivery Laboratory Professor, in collaboration with Toray Industries, Inc. and Department of Pain Control Research, The Jikei University School of Medicine Professor, Yasuhito Kamizono, and colleagues, confirmed in a preclinical study that a polymer-bound anticancer drug (code name: TXB-001) shows strong anticancer activity against several solid tumor types In a preclinical study conducted in collaboration with Dr. Yasuhito Uesono and his colleagues, it was confirmed that a polymer-bound anticancer drug (code name: TXB-001) exhibits strong anticancer activity against several solid tumor types and that it significantly reduces several toxicities, including cardiotoxicity, observed with existing anthracyclines.

To the topic List